ClinicalTrials.gg
RecruitingNCT07345702BAOCHE-LCUpdated Jul 30, 2026

Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct

An observational study in Basilar Artery Occlusion, Ischemic Stroke and Large Core Infarct, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Xuanwu Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
518
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing — 30 open to participants now, 31 under way, 2 of them phase 3. Ischemic Stroke · Xuanwu Hospital, Beijing.

Planned enrollment
8th of 24
518 · median 350
Started
2026
with 9 others
Observational
24 of 52
15 open now
Primary completion
2026-10
later than 8 of 30 live
Registered
44th of 52
by date

Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 8th largest by planned enrollment of the 24 observational ones that give a count, is one of 10 that started in 2026, is one of 24 observational ones, reaches primary completion later than 8 of the 30 other live ones, and was the 44th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

30 of the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

This multicenter retrospective registry study evaluates the safety and effectiveness of endovascular therapy versus medical therapy for acute large-core basilar artery occlusion. It also investigates clinical, imaging, and laboratory factors associated with functional outcomes and mortality. Patients are grouped according to the treatment received in routine clinical practice.

03

Conditions studied

  • Basilar Artery Occlusion
  • Ischemic Stroke
  • Large Core Infarct

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥18 years) with imaging-confirmed acute vertebrobasilar occlusion and large-core infarction (pc-ASPECTS 0-5) treated within 7 days of symptom onset/last known well at participating centers in China. Patients are identified retrospectively from routine clinical practice and classified according to treatment received: endovascular therapy plus standard medical management versus standard medical management alone.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, men or women.
  2. Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
  3. Time from symptom onset (or last known well) to treatment (endovascular therapy or medical therapy) ≤7 days.
  4. Patients with large core infarction in the posterior circulation, defined as a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) score of 0-5 on CT angiography source images or MR with diffusion-weighted imaging or non-contrast CT.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with occlusions in both anterior and posterior circulation.
  2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
  3. Missing key clinical information (e.g., unavailable baseline NIHSS, unclear symptom onset/last known well time, or missing major treatment information including whether EVT was performed).
  4. Baseline NIHSS score \<6.
  5. Woman of who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
  6. Missing follow-up outcomes at 90 days.
  7. Any other condition judged by investigators to substantially affect analysis or interpretation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
518 participants (estimated)
Patient registry
No

Groups and cohorts

  • Endovascular Therapy

    Procedure: Endovascular Therapy

  • Best Medical Treatment Alone

Interventions

  • ProcedureEndovascular Therapy

    Endovascular therapy performed as part of routine clinical care for acute basilar artery occlusion, including mechanical thrombectomy with stent retriever and/or aspiration. Rescue angioplasty and/or intracranial stenting may be used at the operator's discretion. Peri-procedural management and concomitant medical therapy follow local standard practice.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Achieving mRS 0-3 at 90 Days

    The modified Rankin scale (range, 0 \[no symptoms\] to 6 \[death\]). Higher scores mean a worse outcome.

    Time frame: 90 days

Secondary outcomes

  1. Ordinal Shift analysis of mRS at 90 days

    The modified Rankin scale (range, 0 \[no symptoms\] to 6 \[death\])

    Time frame: 90 days

  2. Rate of All-Cause Mortality at 90 Days

    Death from any cause within 90 days.

    Time frame: 90 days

  3. Rate of Symptomatic Intracranial Hemorrhage

    Time frame: 24 (-2/+12) hours

  4. Proportion of Patients Achieving mRS 0-3 at 1 year

    The modified Rankin scale (range, 0 \[no symptoms\] to 6 \[death\]). Higher scores mean a worse outcome.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The study is proceeding.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 16, 2026
StartActual
Jan 31, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07345702
Responsible party
Chuanhui Li (Associate Professor, Xuanwu Hospital, Captimal Medical University, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Jan 16, 2026
Start date
Jan 31, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Jul 30, 2026

Study contacts

Chuanhui Li
Contact
lichuanhui@xwh.ccmu.edu.cn
15210439828

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion